AWM
REGN icon

Apollon Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Apollon Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96M Buy
3,831
+264
+7% +$202K 0.05% 303
2025
Q4 		$2.75M Buy
3,567
+104
+3% +$70.6K 0.05% 308
2025
Q3 		$1.95M Buy
3,463
+115
+3% +$65K 0.03% 385
2025
Q2 		$1.76M Sell
3,348
-146
-4% -$81.5K 0.03% 386
2025
Q1 		$2.22M Buy
3,494
+1,772
+103% +$1.22M 0.05% 313
2024
Q4 		$1.23M Buy
1,722
+130
+8% +$109K 0.03% 448
2024
Q3 		$1.67M Sell
1,592
-83
-5% -$92.4K 0.05% 348
2024
Q2 		$1.76M Sell
1,675
-30
-2% -$29.1K 0.05% 323
2024
Q1 		$1.64M Buy
1,705
+418
+32% +$397K 0.05% 336
2023
Q4 		$1.13M Buy
1,287
+314
+32% +$259K 0.04% 411
2023
Q3 		$801K Buy
973
+62
+7% +$48.7K 0.04% 422
2023
Q2 		$655K Buy
911
+151
+20% +$116K 0.03% 525
2023
Q1 		$624K Sell
760
-40
-5% -$30.2K 0.04% 465
2022
Q4 		$577K Sell
800
-562
-41% -$415K 0.04% 463
2022
Q3 		$938K Buy
1,362
+110
+9% +$69.2K 0.08% 268
2022
Q2 		$740K Sell
1,252
-68
-5% -$44.2K 0.06% 333
2022
Q1 		$922K Sell
1,320
-30
-2% -$19K 0.07% 307
2021
Q4 		$853K Buy
1,350
+130
+11% +$79.9K 0.06% 323
2021
Q3 		$738K Sell
1,220
-251
-17% -$156K 0.1% 190
2021
Q2 		$822K Sell
1,471
-318
-18% -$161K 0.15% 134
2021
Q1 		$846K Buy
+1,789
New +$871K 0.16% 122
2020
Q3 		– Sell
-16
Closed -$10K – 568
2020
Q2 		$10K Buy
+16
New +$9.08K 0.01% 499

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Apollon Wealth Management's REGN Position: Q1 2026 in Review

Apollon Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 7.4% in Q1 2026, buying an estimated $202K and bringing the position to 3,831 shares worth $2.96M. The position accounts for 0.05% of the portfolio, ranked #303.

Apollon Wealth Management first reported a position in REGN in Q2 2020 and has held it in 22 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Apollon Wealth Management held 3,831 shares of Regeneron Pharmaceuticals worth $2.96M as of Q1 2026.
  • Apollon Wealth Management bought 264 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $202K.
  • Regeneron Pharmaceuticals made up 0.05% of Apollon Wealth Management's portfolio in Q1 2026, its #303 holding.
  • Apollon Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 22 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Apollon Wealth Management's 13F filing for Q1 2026, filed 22 Apr 2026.